PDF(Pubmed)
Abstract：
BACKGROUND: Metabolic syndrome (MetS) is a cluster of interconnected risk factors that significantly increase the likelihood of cardiovascular disease and type 2 diabetes. Taurine has emerged as a potential therapeutic agent for MetS. This meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the effects of taurine supplementation on MetS-related parameters.
METHODS: We conducted electronic searches through databases like Embase, PubMed, Web of Science, Cochrane CENTRAL, and ClinicalTrials.gov, encompassing publications up to December 1, 2023. Our analysis focused on established MetS diagnostic criteria, including systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C). Meta-regression explored potential dose-dependent relationships based on the total taurine dose administered during the treatment period. We also assessed secondary outcomes like body composition, lipid profile, and glycemic control.
RESULTS: Our analysis included 1024 participants from 25 RCTs. The daily dosage of taurine in the studies ranged from 0.5 g/day to 6 g/day, with follow-up periods varying between 5 and 365 days. Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155). Meta-regression analysis revealed a dose-dependent reduction in DBP (coefficient = -0.0108 mmHg per g, p = 0.0297) and FBG (coefficient = -0.0445 mg/dL per g, p = 0.0273). No significant adverse effects were observed compared to the control group.
CONCLUSIONS: Taurine supplementation exhibits positive effects on multiple MetS-related factors, making it a potential dietary addition for individuals at risk of or already experiencing MetS. Future research may explore dose-optimization strategies and potential long-term benefits of taurine for MetS management.
METHODS: We conducted electronic searches through databases like Embase, PubMed, Web of Science, Cochrane CENTRAL, and ClinicalTrials.gov, encompassing publications up to December 1, 2023. Our analysis focused on established MetS diagnostic criteria, including systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C). Meta-regression explored potential dose-dependent relationships based on the total taurine dose administered during the treatment period. We also assessed secondary outcomes like body composition, lipid profile, and glycemic control.
RESULTS: Our analysis included 1024 participants from 25 RCTs. The daily dosage of taurine in the studies ranged from 0.5 g/day to 6 g/day, with follow-up periods varying between 5 and 365 days. Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155). Meta-regression analysis revealed a dose-dependent reduction in DBP (coefficient = -0.0108 mmHg per g, p = 0.0297) and FBG (coefficient = -0.0445 mg/dL per g, p = 0.0273). No significant adverse effects were observed compared to the control group.
CONCLUSIONS: Taurine supplementation exhibits positive effects on multiple MetS-related factors, making it a potential dietary addition for individuals at risk of or already experiencing MetS. Future research may explore dose-optimization strategies and potential long-term benefits of taurine for MetS management.
摘要：
背景：代谢综合征（MetS）是一组相互关联的危险因素，它们显着增加了心血管疾病和2型糖尿病的可能性。牛磺酸已成为MetS的潜在治疗剂。这项随机对照试验（RCTs）的荟萃分析旨在评估补充牛磺酸对MetS相关参数的影响。
方法：我们通过Embase等数据库进行了电子搜索，PubMed,WebofScience,科克伦中部,和ClinicalTrials.gov,涵盖截至2023年12月1日的出版物。我们的分析集中在既定的MetS诊断标准上，包括收缩压（SBP），舒张压（DBP），空腹血糖（FBG），甘油三酯（TG），和高密度脂蛋白胆固醇（HDL-C）。Meta回归研究了基于治疗期间牛磺酸总剂量的潜在剂量依赖性关系。我们还评估了次要结果，如身体成分，血脂谱,和血糖控制。
结果：我们的分析包括来自25个随机对照试验的1024名参与者。研究中牛磺酸的日剂量范围从0.5克/天到6克/天，随访时间在5到365天之间。与对照组相比，补充牛磺酸显示SBP的统计学显着降低（加权平均差[WMD]=-3.999mmHg，95%置信区间[CI]=-7.293至-0.706，p=0.017)，DBP(WMD=-1.509mmHg,95%CI=-2.479至-0.539，p=0.002），FBG(WMD:-5.882mg/dL,95%CI：-10.747至-1.018，p=0.018），TG（WMD：-18.315mg/dL，95%CI：-25.628至-11.002，p<0.001），但在HDL-C中没有（WMD：0.644mg/dl，95%CI：-0.244至1.532，p=0.155）。荟萃回归分析显示DBP的剂量依赖性降低（系数=-0.0108mmHg/g，p=0.0297）和FBG（系数=-0.0445mg/dL/g，p=0.0273)。与对照组相比，未观察到明显的不良反应。
结论：牛磺酸补充剂对多种MetS相关因素具有积极作用，使其成为有风险或已经经历MetS的个体的潜在膳食添加剂。未来的研究可能会探索剂量优化策略和牛磺酸对MetS管理的潜在长期益处。
方法：我们通过Embase等数据库进行了电子搜索，PubMed,WebofScience,科克伦中部,和ClinicalTrials.gov,涵盖截至2023年12月1日的出版物。我们的分析集中在既定的MetS诊断标准上，包括收缩压（SBP），舒张压（DBP），空腹血糖（FBG），甘油三酯（TG），和高密度脂蛋白胆固醇（HDL-C）。Meta回归研究了基于治疗期间牛磺酸总剂量的潜在剂量依赖性关系。我们还评估了次要结果，如身体成分，血脂谱,和血糖控制。
结果：我们的分析包括来自25个随机对照试验的1024名参与者。研究中牛磺酸的日剂量范围从0.5克/天到6克/天，随访时间在5到365天之间。与对照组相比，补充牛磺酸显示SBP的统计学显着降低（加权平均差[WMD]=-3.999mmHg，95%置信区间[CI]=-7.293至-0.706，p=0.017)，DBP(WMD=-1.509mmHg,95%CI=-2.479至-0.539，p=0.002），FBG(WMD:-5.882mg/dL,95%CI：-10.747至-1.018，p=0.018），TG（WMD：-18.315mg/dL，95%CI：-25.628至-11.002，p<0.001），但在HDL-C中没有（WMD：0.644mg/dl，95%CI：-0.244至1.532，p=0.155）。荟萃回归分析显示DBP的剂量依赖性降低（系数=-0.0108mmHg/g，p=0.0297）和FBG（系数=-0.0445mg/dL/g，p=0.0273)。与对照组相比，未观察到明显的不良反应。
结论：牛磺酸补充剂对多种MetS相关因素具有积极作用，使其成为有风险或已经经历MetS的个体的潜在膳食添加剂。未来的研究可能会探索剂量优化策略和牛磺酸对MetS管理的潜在长期益处。
